| Literature DB >> 20129627 |
Kiyoe Ohta1, Sadako Kuno, Seiji Inoue, Erika Ikeda, Aya Fujinami, Mitsuhiro Ohta.
Abstract
In Parkinson's disease, cell death is selectively induced in mesencephalic nigral dopaminergic neurons. At present, no disease modifying therapy or radical treatment has been found for this disease. Some dopamine agonists may have a neuroprotective action in cultured cells and animal models. In the present study, we examined stimulating effects of a non-ergoline D(2) dopamine agonist, ropinirole, on synthesis/secretion of neurotrophic factors, including NGF, BDNF, and GDNF, in cultured mouse astrocytes. These effects were compared with those of ergoline dopamine agonists, SKF-38393, a D(1) agonist, bromocriptine, D(2) agonist, and apomorphine, D(1)/D(2) agonist. Ropinirole elevated GDNF levels to 4-fold, and NGF levels to 6.3-fold, compared with the control group. Of the dopamine agonists examined, ropinirole produced and secreted more GDNF than a 1.8-fold greater amount of apomorphine, a lesser amount of bromocriptine, or a 2.8-fold greater amount of SKF-38393, which served as the control group. Copyright 2010. Published by Elsevier B.V.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20129627 DOI： 10.1016/j.jns.2010.01.013
Source DB: PubMed Journal: J Neurol Sci ISSN： 0022-510X Impact factor: 3.181